Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

被引：66

作者：

Brill, Ethan ^{[1
]}

Yokoyama, Takuhei ^{[1
]}

Nair, Jayakumar ^{[1
]}

Yu, Minshu ^{[1
]}

Ahn, Yeong-Ran ^{[1
]}

Lee, Jung-Min ^{[1
]}

机构：

[1] NCI, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

ONCOTARGET | 2017年 / 8卷 / 67期

基金：

美国国家卫生研究院;

关键词：

cell cycle checkpoint kinase inhibitor; prexasertib; LY2606368; PARP inhibitor; olaparib; DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; REPLICATION CATASTROPHE; OPEN-LABEL; CHK1; CARCINOMA; OLAPARIB; MUTATIONS; DEATH; RADIOSENSITIZATION;

D O I：

10.18632/oncotarget.22195

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PARP inhibitors (PARPi) have been effective in high-grade serous ovarian cancer (HGSOC), although clinical activity is limited against BRCA wild type HGSOC. The nearly universal loss of normal p53 regulation in HGSOCs causes dysfunction in the G1/S checkpoint, making tumor cells reliant on Chk1-mediated G2/M cell cycle arrest for DNA repair. Therefore, Chk1 is a reasonable target for a combination strategy with PARPi in treating BRCA wild type HGSOC. Here we investigated the combination of prexasertib mesylate monohydrate (LY2606368), a Chk1 and Chk2 inhibitor, and a PARP inhibitor, olaparib, in HGSOC cell lines (OVCAR3, OV90, PEO1 and PEO4) using clinically attainable concentrations. Our findings showed combination treatment synergistically decreased cell viability in all cell lines and induced greater DNA damage and apoptosis than the control and/or monotherapies (p< 0.05). Treatment with olaparib in BRCA wild type HGSOC cells caused formation of Rad51 foci, whereas the combination treatment with prexasertib inhibited transnuclear localization of Rad51, a key protein in homologous recombination repair. Overall, our data provide evidence that prexasertib and olaparib combination resulted in synergistic cytotoxic effects against BRCA wild type HGSOC cells through reduced Rad51 foci formation and greater induction of apoptosis. This may be a novel therapeutic strategy for HGSOC.

引用

页码：111026 / 111040

页数：15

共 65 条

[1]

[Anonymous], 2016, ANN ONCOL

[2] The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage [J].

Bahassi, E. M. ;

Ovesen, J. L. ;

Riesenberg, A. L. ;

Bernstein, W. Z. ;

Hasty, P. E. ;

Stambrook, P. J. .

ONCOGENE, 2008, 27 (28) :3977-3985

[3] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[4] PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells [J].

Booth, Laurence ;

Cruickshanks, Nichola ;

Ridder, Thomas ;

Dai, Yun ;

Grant, Steven ;

Dent, Paul .

CANCER BIOLOGY & THERAPY, 2013, 14 (05) :458-465

[5] Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].

Chou, Ting-Chao .

PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681

[6] Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method [J].

Chou, Ting-Chao .

CANCER RESEARCH, 2010, 70 (02) :440-446

[7] Cdk2 Is Required for p53-Independent G2/M Checkpoint Control [J].

Chung, Jon H. ;

Bunz, Fred .

PLOS GENETICS, 2010, 6 (02)

[8] Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma [J].

Cooke, S. L. ;

Ng, C. K. Y. ;

Melnyk, N. ;

Garcia, M. J. ;

Hardcastle, T. ;

Temple, J. ;

Langdon, S. ;

Huntsman, D. ;

Brenton, J. D. .

ONCOGENE, 2010, 29 (35) :4905-4913

[9] PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors [J].

Dedes, Konstantin J. ;

Wetterskog, Daniel ;

Mendes-Pereira, Ana M. ;

Natrajan, Rachael ;

Lambros, Maryou B. ;

Geyer, Felipe C. ;

Vatcheva, Radost ;

Savage, Kay ;

Mackay, Alan ;

Lord, Christopher J. ;

Ashworth, Alan ;

Reis-Filho, Jorge S. .

SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (53)

[10] Induction and inhibition of the pan-nuclear gamma-H2AX response in resting human peripheral blood lymphocytes after X-ray irradiation [J].

Ding, D. ;

Zhang, Y. ;

Wang, J. ;

Zhang, X. ;

Gao, Y. ;

Yin, L. ;

Li, Q. ;

Li, J. ;

Chen, H. .

CELL DEATH DISCOVERY, 2016, 2

← 1 2 3 4 5 6 7 →